COMMUNIQUÉS West-GlobeNewswire

Theratechnologies Announces Update on its Preclinical Oncology Research Program
22/03/2024
Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX [...]
Theratechnologies fait le point sur son programme de recherche préclinique en oncologie
22/03/2024
La Société continue d’orienter ses efforts sur la commercialisation alors qu’elle cherche des partenaires pour faire progresser la R-D MONTRÉAL, 22 mars 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« [...]
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
22/03/2024
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid [...]
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
22/03/2024
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO [...]
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22/03/2024
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the [...]
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
22/03/2024
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times reports telomere [...]
VA STAND Act introduced in the United States Senate
22/03/2024
Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord Injury MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, [...]
Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
22/03/2024
New studies at Mount Sinai Health System and Penn Medicine investigate how the brain controls movement NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience [...]
Ultimovacs ASA: Mandatory notification of trade by primary insider
22/03/2024
Oslo, March 22, 2024, Board member Henrik Schüssler and primary insider in Ultimovacs ASA, has today through FireH AS bought 50,000 shares in the company at a price of NOK 6.398 per share. Following this transaction, [...]
Retrieve Medical Holdings, Inc. (RMHI) Announces Study Update Results Utilizing Retrieve Dx ™ Software
22/03/2024
BEDMINSTER, N.J. , March 22, 2024 (GLOBE NEWSWIRE) -- Retrieve Medical Holdings, Inc. (RMHI), the developer of Retrieve Dx, a real-time, cloud-based CDI (Clinical Documentation Integrity) application that improves [...]
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
22/03/2024
Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m [...]
American Shared Hospital Services Announces Fourth Quarter 2023 Earnings Conference Call
22/03/2024
Conference Call on Thursday, March 28th at 12:00 pm ET / 9:00 am PT SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey [...]
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
22/03/2024
SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark [...]
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22/03/2024
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular [...]
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
22/03/2024
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results [...]
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
22/03/2024
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( [...]
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
22/03/2024
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer [...]
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
22/03/2024
Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy 1-5 If approved, Fabhalta [...]
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22/03/2024
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2 data with [...]

Pages